Synonyms: GSK-2636771
Compound class:
Synthetic organic
Comment: GSK2636771 is a potent, orally bioavailable, PI3Kβ-selective inhibitor, with anticancer effects in PTEN null cells [2].
|
|
No information available. |
Summary of Clinical Use ![]() |
GSK2636771 has progressed to Phase 2 clinical trial (October 2018). Click here to link to ClinicalTrials.gov's full list of GSK2636771 trials. |